Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2009

View Archived Issues

Novel flavivirus-based vaccine protects against Dengue virus type 2 in mice

Pharmacokinetics, toxicity of IQP-0410 investigated in dogs

Alfadolone confers antinociception in rat models of inflammation

Avexa provides update on merger with Progen

Bavituximab achieves primary endpoint in phase II breast cancer study

Living Cell Technologies reports interim Diabecell Implants results

Prezista available for pediatric patients as part of HIV combination therapy

Genta submits tesetaxel trial proposal for SPA in advanced gastric cancer

Endo signs research collaboration agreements with Harvard University and Aurigene

Oxygen to file in Switzerland for phase II clinical trial of Oxycyte in TBI

TorreyPines reports positive results from phase I clinical trial of NGX-426 in healthy subjects

VasoGenix selects lead CGRP agonist analogue to develop for heart failure

Chewable antiretroviral therapy combination viable in HIV-infected children

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....